Screening bone marrow samples for abnormal lymphoid populations and myelodysplasia‐related features with one 10‐color 14‐antibody screening tube

Rajab, Amr; Porwit, Anna

doi:10.1002/cyto.b.21233

Cited by 33 publications

(54 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The 10-colour, 14-antibody screen used by Toronto General Hospital focuses on the detection of abnormal antigen patterns not seen in normal/reactive bone marrows, and has been validated for screening for acute leukaemia, lymphoma and myelodysplastic syndrome10 11 We agree that a thorough validation process which includes the development and training of staff to use standardised analysis templates designed to clearly separate normal from abnormal populations is key to a successful implementation. Our laboratory also plans to incorporate key features of the Toyota Production System in order to facilitate a lean workflow.…”

Section: Discussionmentioning

confidence: 99%

Aligning the flow cytometric evaluation with the diagnostic need: an evidence-based approach

2017

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Aligning the flow cytometric evaluation with the diagnostic need: an evidence-based approach

2017

View full text Add to dashboard Cite

show abstract

“…We have extended this concept to detect at least some myelodysplasia‐related features as well as the four‐parameter MDS flow cytometry score (also termed the Ogata score) recommended for screening purposes by the International/ELN Working Group for Flow Cytometry . We and other groups confirmed the utility of this relatively simple scoring system . The composition of the comprehensive 3‐tube panel follows detailed guidelines of the IMDSFlow group .…”

Section: Introductionmentioning

confidence: 71%

Flow cytometry immunophenotyping in integrated diagnostics of patients with newly diagnosed cytopenia: one tube 10‐color 14‐antibody screening panel and 3‐tube extensive panel for detection ofMDS‐related features

Porwit

Rajab

2015

Int J Lab Hematology

View full text Add to dashboard Cite

Summary Acute leukemia, myelodysplastic syndromes (MDS), myeloproliferative neoplasms and lymphomas are the most prevalent diagnoses in adults presenting with new onset cytopenia. Here, we describe two 10‐color panels of surface markers (screening and comprehensive panel) applied at the Flow Cytometry Laboratory, University Health Network, Toronto, ON, Canada. A 10‐color flow cytometry is applied using the stain–lyse–wash sample preparation method. In patients with <10% blasts and no clear involvement by hematological malignancy based on cytomorphological evaluation of bone marrow (BM) smear, the recently published one‐tube 10‐color 14‐antibody screening panel is applied. This panel allows detection of major B‐ and T‐cell abnormalities, enumeration of cells in blast region (CD45 dim), and gives insight into myeloid BM compartment, including calculation of four‐parameter score for MDS‐related abnormalities. In patients who present with ≥10 – <20% blasts in blood or BM smears, a comprehensive three‐tube panel of surface markers is used up front. The analysis is focused on the detection of abnormal antigen expression patterns not seen in normal/reactive BM, according to the guidelines developed by International/European LeukemiaNet Working Group for Flow Cytometry in MDS. In patients with ≥20% blasts, an additional tube is added to allow the detection of cytoplasmic markers necessary to diagnose mixed phenotype acute leukemia.

show abstract

“…Leukemia-associated immunophenotypes in myeloid stem cells and abnormal maturation patterns in mature myeloid cells as demonstrated by flow cytometry have recently been used to help diagnose myelodysplastic syndrome (MDS) and myeloproliferative neoplasms. [35][36][37] Hairy cell leukemia cells express CD25, CD103, and bright CD11c and CD22, a pattern not observed in other B-cell non-Hodgkin lymphomas. Mantle cell lymphoma, an aggressive lymphoma requiring more intense chemotherapy, can be distinguished from other, more indolent mature B-cell non-Hodgkin lymphomas with similar morphology.…”

Section: 34mentioning

confidence: 87%

Multimodality Technologies in the Assessment of Hematolymphoid Neoplasms

Li¹,

Jaye²,

Bradley³

et al. 2017

Archives of Pathology &Amp; Laboratory Medicine

View full text Add to dashboard Cite

Accurate assessment of tissues for hematolymphoid neoplasms requires an integrated multiparameter approach. Although morphologic examination by light microscopy remains the mainstay of initial assessment for hematolymphoid neoplasms, immunophenotypic analysis by immunohistochemistry and/or flow cytometry is essential to determine the pattern of differentiation and to detect minimal disease when morphology is inconclusive. In some cases, immunophenotypic analysis provides additional information for targeted immunotherapy and prognostication. Genotypic studies, including cytogenetics, fluorescence in situ hybridization, DNA microarray, polymerase chain reaction, and/or next-generation sequencing, are also imperative for subclassification of the genetically defined disease entities in the current World Health Organization classification of hematolymphoid neoplasms. Moreover, genotypic studies can establish clonality, stratify patients to determine appropriate treatment, and monitor patients for treatment response.

show abstract

Screening bone marrow samples for abnormal lymphoid populations and myelodysplasia‐related features with one 10‐color 14‐antibody screening tube

Cited by 33 publications

References 28 publications

Aligning the flow cytometric evaluation with the diagnostic need: an evidence-based approach

Aligning the flow cytometric evaluation with the diagnostic need: an evidence-based approach

Flow cytometry immunophenotyping in integrated diagnostics of patients with newly diagnosed cytopenia: one tube 10‐color 14‐antibody screening panel and 3‐tube extensive panel for detection ofMDS‐related features

Multimodality Technologies in the Assessment of Hematolymphoid Neoplasms

Contact Info

Product

Resources

About